Book Online or Call 1-855-SAUSALITO

Sign In  |  Register  |  About Sausalito  |  Contact Us

Sausalito, CA
September 01, 2020 1:41pm
7-Day Forecast | Traffic

  • Search Hotels in Sausalito

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Tonix Pharmaceuticals Holding Corp. - Common Stock (NQ:TNXP)

28.00 +4.90 (+21.21%)
Streaming Delayed Price Updated: 4:00 PM EDT, May 16, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Tonix Pharmaceuticals Holding Corp. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
14 15 Next >
SOUN Stock Alert: SoundHound AI Pays Off Debt Early
SoundHound AI stock is up on Monday as SOUN investors celebrate the company paying off all of its outstanding debts with cash to spare. 
Via InvestorPlace
Topics Artificial Intelligence
Exposures Artificial Intelligence
Why Is Tonix Pharmaceuticals (TNXP) Stock Down 31% Today?
Tonix Pharmaceuticals stock is down on Monday after shares of TNXP underwent a one-for-32 reverse stock split to avoid delisting. 
Via InvestorPlace
US Stocks Mixed; Perion Network Shares Plunge
Via Benzinga
TNXP Stock Earnings: Tonix Pharmaceuticals Beats EPS, Misses Revenue for Q1 2024
TNXP stock results show that Tonix Pharmaceuticals beat analyst estimates for earnings per share but missed on revenue for the first quarter of 2024. 
Via InvestorPlace
3 Biotech Stocks to Dump Before They Go to Zero
These biotech stocks to sell are burning through cash at an alarming rate and seem destined for zero, making them prime targets for selling. 
Via InvestorPlace
TNXP Stock Earnings: Tonix Pharmaceuticals Beats EPS, Misses Revenue for Q4 2023
TNXP stock results show that Tonix Pharmaceuticals beat analyst estimates for earnings per share but missed on revenue for the fourth quarter of 2023. 
Via InvestorPlace
New Drug Study Shows Improving Sleep Quality Can Relieve Fibromyalgia Pain
Via ACCESSWIRE
Tonix Drug Shown To Relieve Pain in Fibromyalgia Without Risk of Addiction
Via ACCESSWIRE
Hope On The Horizon: Tonix Pharmaceuticals (NASDAQ:TNXP) Could Be On the Cusp of Changing Fibromyalgia Treatment Options With TNX-102 SL
Via ACCESSWIRE
Tonix Pharmaceuticals Stock (TNXP) Hits A New All-Time Low: What's Going On?
Tonix Pharmaceuticals shares are trading lower by 7.2% Monday. The company last week announced the pricing of a $4.4 million registered direct offering. 
Via Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
Via Benzinga
Why Kodiak Sciences Shares Are Trading Lower By Around 20%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Shares of Kodiak Sciences Inc. (NASDAQ: KOD) fell sharply during Thursday’s session after the company reported a wider-than-expected fourth-quarter loss. Kodiak Sciences posted a quarterly loss of... 
Via Benzinga
Why Tonix Pharmaceuticals Stock (TNXP) Is Getting Obliterated
Tonix Pharmaceuticals shares are trading lower by 22.3% Thursday afternoon. The company announced the pricing of a $4.4 million registered direct offering. 
Via Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session
Via Benzinga
3 Mind-Blowing Stocks That Could Turn $1,000 Into $1 Million
If you want the chance at possible absurd returns, then consider gambling on these stocks to turn $1,000 into $1 million. 
Via InvestorPlace
New to the Street TV Series on Bloomberg and Fox Business, Innovative Companies Spotlighted: ACXP, TNXP, PETV, SWISF, GEVI, CLNV
Via AB Newswire
3 Top Penny Stocks for 5,000% Upside in 2024 and Beyond
When you want to light your afterburners, these ideas will do the trick. 
Via InvestorPlace
Global Fibromyalgia Treatment Market Expected to Reach $4.6 billion by 2032
EQNX::TICKER_START (NASDAQ:TNXP),(NYSE:PFE),(NYSE:LLY),(NYSE:ABBV),(NYSE:MRK) EQNX::TICKER_END 
Via FinancialNewsMedia
Leading The Charge: Tonix Pharmaceuticals And The Future Of CNS Therapeutics
Via Get News
Tonix Drug Shown To Relieve Pain in Fibromyalgia Without Getting Patients Addicted In Phase 3 Trial
The following post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and Tonix Pharmaceuticals Holding Corp, a financial partner of Benzinga. The... 
Via Benzinga
Global Fibromyalgia Treatment Market Expected to Reach $4.6 billion by 2032
From FN Media Group LLC
Via GlobeNewswire
New Hope For Fibromyalgia Patients: Tonix Details Results Of Second Successful Phase 3 Trial And Plans To File For FDA Approval
Via ACCESSWIRE
New Hope For Fibromyalgia Patients? Tonix Details Results Of Second Successful Phase 3 Trial And Plans To File For FDA Approval
The following post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and Tonix Pharmaceuticals Holding Corp, a financial partner of Benzinga. The... 
Via Benzinga
Exposures Product Safety
Why Tonix Pharmaceuticals (TNXP) Shares Are Plummeting
Tonix Pharmaceuticals Holding Corp (NASDAQ: TNXP) shares are trading lower by 30.8% to $0.41 during Wednesday's session after the company announced it is securing up to $144 million in funding through... 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
Via Benzinga
Hope On The Horizon: Tonix Pharmaceuticals (NASDAQ: TNXP) Could Be On the Cusp of Changing Fibromyalgia Treatment Options With TNX-102 SL
The following post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a financial partner of Benzinga. The sponsored content team works to ensure... 
Via Benzinga
12 Health Care Stocks Moving In Thursday's After-Market Session
Via Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
Via Benzinga
Why Extreme Networks Shares Are Trading Lower By Around 15%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Gainers 
Via Benzinga
Why Tonix Pharmaceuticals (TNXP) Stock Is Falling Sharply Today
Tonix Pharmaceuticals Holding Corp (NASDAQ: TNXP) shares are trading lower by 17% to $0.49 Wednesday morning. The company late Tuesday announced the topline results of a Phase 2 study for TNX-601 ER, a... 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
14 15 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Photos copyright by Jay Graham Photographer
Copyright © 2010-2020 Sausalito.com & California Media Partners, LLC. All rights reserved.